B型肝炎ワクチンの世界市場 - 成長、将来展望、競合分析（2022年～2030年）

B型肝炎感染予防に対する意識の高まり、各国政府の予防接種の義務化、B型肝炎ワクチンの国家予防接種スケジュールへの組み入れなどの要因が、世界のB型肝炎ワクチン市場の成長を後押ししています。

当レポートでは、世界のB型肝炎ワクチン市場について調査し、市場動向、競合情報、セグメント分析、新興動向、技術分析、企業プロファイルなどの情報を提供しています。

目次

第1章 序文

• レポート概要
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 市場スナップショット：世界のB型肝炎ワクチン市場
• 世界のB型肝炎ワクチン市場：組成別（2021年）
• 世界のB型肝炎ワクチン市場：エンドユーザー年齢別（2021年）
• 世界のB型肝炎ワクチン市場：地域別（2021年）
• 魅力的な投資提案：地域別（2021年）

第3章 B型肝炎ワクチン市場：競合分析

• 主要なB型肝炎ワクチン市場ベンダーの市場ポジショニング
• B型肝炎ワクチン市場ベンダーの採用戦略
• 主要な業界戦略
• 階層分析：2021年対2030年

第4章 B型肝炎ワクチン市場：マクロ分析と市場力学

• イントロダクション
• 世界のB型肝炎ワクチン市場金額（2020年～2030年）
• 市場力学
  • 市場促進要因
  • 市場抑制要因
  • 主な課題
  • 主な機会
• 促進要因と抑制要因の影響分析
• シーソー分析

第5章 B型肝炎ワクチン市場：組成別（2020年～2030年）

• 市場概要
• 成長と収益分析：2021年対2030年
• 市場セグメンテーション
  • 混合ワクチン
  • 単味ワクチン

第6章 B型肝炎ワクチン市場：エンドユーザー年齢別（2020年～2030年）

• 市場概要
• 成長と収益分析：2021年対2030年
• 市場セグメンテーション
  • 成人用B型肝炎ワクチン
  • 小児用B型肝炎ワクチン

第7章 北米のB型肝炎ワクチン市場（2020年～2030年）

• 市場概要
• B型肝炎ワクチン市場：組成別（2020年～2030年）
• B型肝炎ワクチン市場：エンドユーザー年齢別（2020年～2030年）
• B型肝炎ワクチン市場：地域別（2020年～2030年）
  • 北米

第8章 英国・欧州連合のB型肝炎ワクチン市場（2020年～2030年）

• 市場概要
• B型肝炎ワクチン市場：組成別（2020年～2030年）
• B型肝炎ワクチン市場：エンドユーザー年齢別（2020年～2030年）
• B型肝炎ワクチン市場：地域別（2020年～2030年）
  • 英国・欧州連合

第9章 アジア太平洋のB型肝炎ワクチン市場（2020年～2030年）

• 市場概要
• B型肝炎ワクチン市場：組成別（2020年～2030年）
• B型肝炎ワクチン市場：エンドユーザー年齢別（2020年～2030年）
• B型肝炎ワクチン市場：地域別（2020年～2030年）
  • アジア太平洋

第10章 ラテンアメリカのB型肝炎ワクチン市場（2020年～2030年）

• 市場概要
• B型肝炎ワクチン市場：組成別（2020年～2030年）
• B型肝炎ワクチン市場：エンドユーザー年齢別（2020年～2030年）
• B型肝炎ワクチン市場：地域別（2020年～2030年）
  • ラテンアメリカ

第11章 中東・アフリカのB型肝炎ワクチン市場（2020年～2030年）

• 市場概要
• B型肝炎ワクチン市場：組成別（2020年～2030年）
• B型肝炎ワクチン市場：エンドユーザー年齢別（2020年～2030年）
• B型肝炎ワクチン市場：地域別（2020年～2030年）
  • 中東・アフリカ

第12章 企業プロファイル

• Beijing Minhai Biotechnology
• CSL Limited
• Dynavax Technologies
• Emergent Biosolutions
• GlaxoSmithKline Biologicals
• Merck & Co, Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi Pasteur
• Serum Institute of India
• Sinovac Biotech

List of Tables

• TABLE 1 Global Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 2 Global Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 3 North America Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 4 North America Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 5 U.S. Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 6 U.S. Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 7 Canada Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 8 Canada Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 9 Rest of North America Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 10 Rest of North America Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 11 UK and European Union Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 12 UK and European Union Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 13 UK Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 14 UK Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 15 Germany Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 16 Germany Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 17 Spain Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 18 Spain Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 19 Italy Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 20 Italy Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 21 France Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 22 France Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 23 Rest of Europe Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 24 Rest of Europe Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 25 Asia Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 26 Asia Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 27 China Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 28 China Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 29 Japan Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 30 Japan Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 31 India Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 32 India Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 33 Australia Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 34 Australia Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 35 South Korea Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 36 South Korea Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 37 Latin America Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 38 Latin America Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 39 Brazil Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 40 Brazil Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 41 Mexico Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 42 Mexico Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 43 Rest of Latin America Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 44 Rest of Latin America Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 45 Middle East and Africa Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 46 Middle East and Africa Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 47 GCC Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 48 GCC Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 49 Africa Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 50 Africa Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
• TABLE 51 Rest of Middle East and Africa Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
• TABLE 52 Rest of Middle East and Africa Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)

List of Figures

• FIG. 1 Global Hepatitis B Vaccine Market: Market Coverage
• FIG. 2 Research Methodology and Data Sources
• FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
• FIG. 4 Global Hepatitis B Vaccine Market: Quality Assurance
• FIG. 5 Global Hepatitis B Vaccine Market, By Composition, 2021
• FIG. 6 Global Hepatitis B Vaccine Market, By End Users Age, 2021
• FIG. 7 Global Hepatitis B Vaccine Market, By Geography, 2021
• FIG. 8 Market Geographical Opportunity Matrix - Global Hepatitis B Vaccine Market, 2021
• FIG. 9 Market Positioning of Key Hepatitis B Vaccine Market Players, 2021
• FIG. 10 Global Hepatitis B Vaccine Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
• FIG. 11 Global Hepatitis B Vaccine Market, By Composition, 2021 Vs 2030, %
• FIG. 12 Global Hepatitis B Vaccine Market, By End Users Age, 2021 Vs 2030, %
• FIG. 13 U.S. Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
• FIG. 14 Canada Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
• FIG. 15 Rest of North America Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
• FIG. 16 UK Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
• FIG. 17 Germany Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
• FIG. 18 Spain Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
• FIG. 19 Italy Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
• FIG. 20 France Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
• FIG. 21 Rest of Europe Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
• FIG. 22 China Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
• FIG. 23 Japan Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
• FIG. 24 India Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
• FIG. 25 Australia Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
• FIG. 26 South Korea Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
• FIG. 27 Rest of Asia Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
• FIG. 28 Brazil Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
• FIG. 29 Mexico Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
• FIG. 30 Rest of Latin America Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
• FIG. 31 GCC Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
• FIG. 32 Africa Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
• FIG. 33 Rest of Middle East and Africa Hepatitis B Vaccine Market (US$ Million), 2020 - 2030

Factors such as increase in awareness of hepatitis B infection prevention, governments have mandated the immunization and hepatitis B vaccine included in national immunization schedule in many countries driving the market growth of hepatitis B vaccine globally.

The report titled "Hepatitis B Vaccine Market - Growth, Future Prospects and Competitive Analysis, 2022-2030" offers strategic insights into the overall hepatitis B vaccine market along with the market size and estimates for the duration 2020 to 2030. The research study covers in-depth analysis of market segments based on composition, end users age and different geographical regions.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global hepatitis B vaccine market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global hepatitis B vaccine market. This report concludes with company profiles section that highlights major information about the key players engaged in global hepatitis B vaccine market. In-depth competitive environment analysis and historical years (2020) market size data are also provided in the report.

Composition analysis:

Hepatitis B is a life threatening liver infection caused by the hepatitis B virus. Vaccine is most effective than any other treatment in preventing infection. According to WHO (world health organization), prevalence of hepatitis B is highest in Western Pacific and African region however, lowest in American population. Factors such as an increase in awareness of vaccines are expected to contribute the market growth of hepatitis B vaccine globally. For the purpose of study market is segmented on the basis of composition of vaccine such as mono and combination vaccine. Combination vaccines that protect against multiple pathogens, it involves combination of multiple antigens into a single vaccine. Combination vaccine such as Infanrix Hexa, Hexaci ma/Hexyon, Twinrix, Ambirix, Comvax widely used for the prevention of hepatitis B infection. It is observed that, combination vaccine is major revenue generating segment. Factors such as higher patient compliance, reduced number of dose frequency, better disease control, coverage of vaccine under national immunization program and reduced chances of missing immunization are driving the growth of combination vaccine market globally. It is observed that mono vaccines such as Recombi vax HB, Fendrix and Engeri x-B are approved for the treatment of hepatitis B infection.

End user age group analysis:

Hepatitis B virus cause life threatening liver disease, vaccine is more effective than any other treatment in preventing infection. The choice of hepatitis B vaccine varies with the age. Adult Hepatitis B Vaccines are used for active immunization of individuals aged above 18 and 21 in Europe and US respectively. Hepatitis B is one of the most common travelers diseases which can be avoided by vaccine immunization. Governments across the world have mandated the immunization of travelers, which is acting as a growth driver for the hepatitis B vaccines market across the world. It is observed that in base 2016, adult hepatitis B vaccines held largest market share as adults have high risk of developing hepatitis B infections due to end-stage renal disease, drug abuse and HIV infection which is driving the market growth of adult hepatitis B vaccines globally. In terms of immunogenicity, pediatric vaccines differ from adult vaccines. Pediatric hepatitis B vaccines are used for the prevention of hepatitis B infection in infants, toddlers, and adolescents because babies and young children are at higher risk for developing the potentially fatal complications of the infection. It is estimated that pediatric hepatitis B vaccines will show steady growth rate during forecast period. It is observed that pediatric vaccines such Infanrix, hexa, Hexacima/Hexyon, Ambirix, and Comvax. Infanrix hexa are widely accepted in market.

Hepatitis B is life threatening liver disease that can cause acute and chronic liver infection and may lead to cirrhosis and liver cancer. Safe and effective vaccines are available in market to prevent hepatitis B infection. According to World Health Organization (WHO) prevalence of hepatitis B is highest in Western Pacific and in African region more than 6% of the adult population is affected with hepatitis B infection. In South East Asia and European region, it is estimated that 2% and 1.6% of the general population is affected with hepatitis B, respectively. The burden of hepatitis B infection is considerably less in the American population which is approximately 0.7% of the overall population. It is observed that in the base year 2021, North America was major revenue contributing segment. Factors such as higher cost of vaccines, immunization programs and favorable R&D activities driving the market growth in North America. Currently, Asia Pacific is not major revenue generating segment but it is estimated that it will show highest CAGR during forecast period. Rising healthcare awareness, populous countries, increase in awareness of vaccines, government initiative in vaccination program would influence the growth of hepatitis B vaccine market in Asia Pacific region.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Hepatitis B Vaccine market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Hepatitis B Vaccine market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Composition

Combination Vaccines

Mono Vaccines

End Users Age

Adult Hepatitis B vaccines

Paediatric Hepatitis B vaccines

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Hepatitis B Vaccine market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Hepatitis B Vaccine market?

Which is the largest regional market for Hepatitis B Vaccine market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Hepatitis B Vaccine market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Hepatitis B Vaccine market worldwide?

Table of Contents

1. Preface

• 1.1. Report Description
  • 1.1.1. Purpose of the Report
  • 1.1.2. Target Audience
  • 1.1.3. Key Offerings
• 1.2. Market Segmentation
• 1.3. Research Methodology
  • 1.3.1. Phase I - Secondary Research
  • 1.3.2. Phase II - Primary Research
  • 1.3.3. Phase III - Expert Panel Review
  • 1.3.4. Assumptions
  • 1.3.5. Approach Adopted

2. Executive Summary

• 2.1. Market Snapshot: Global Hepatitis B Vaccine Market
• 2.2. Global Hepatitis B Vaccine Market, By Composition, 2021 (US$ Million)
• 2.3. Global Hepatitis B Vaccine Market, By End Users Age, 2021 (US$ Million)
• 2.4. Global Hepatitis B Vaccine Market, By Geography, 2021 (US$ Million)
• 2.5. Attractive Investment Proposition by Geography, 2021

3. Hepatitis B Vaccine Market: Competitive Analysis

• 3.1. Market Positioning of Key Hepatitis B Vaccine Market Vendors
• 3.2. Strategies Adopted by Hepatitis B Vaccine Market Vendors
• 3.3. Key Industry Strategies
• 3.4. Tier Analysis 2021 Versus 2030

4. Hepatitis B Vaccine Market: Macro Analysis & Market Dynamics

• 4.1. Introduction
• 4.2. Global Hepatitis B Vaccine Market Value, 2020 - 2030, (US$ Million)
• 4.3. Market Dynamics
  • 4.3.1. Market Drivers
  • 4.3.2. Market Restraints
  • 4.3.3. Key Challenges
  • 4.3.4. Key Opportunities
• 4.4. Impact Analysis of Drivers and Restraints
• 4.5. See-Saw Analysis

5. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)

• 5.1. Market Overview
• 5.2. Growth & Revenue Analysis: 2021 Versus 2030
• 5.3. Market Segmentation
  • 5.3.1. Combination Vaccines
  • 5.3.2. Mono Vaccines

6. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)

• 6.1. Market Overview
• 6.2. Growth & Revenue Analysis: 2021 Versus 2030
• 6.3. Market Segmentation
  • 6.3.1. Adult Hepatitis B vaccines
  • 6.3.2. Paediatric Hepatitis B vaccines

7. North America Hepatitis B Vaccine Market, 2020-2030, USD (Million)

• 7.1. Market Overview
• 7.2. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
• 7.3. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
• 7.4.Hepatitis B Vaccine Market: By Region, 2020-2030, USD (Million)
  • 7.4.1.North America
    • 7.4.1.1. U.S.
      • 7.4.1.1.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
      • 7.4.1.1.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
    • 7.4.1.2. Canada
      • 7.4.1.2.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
      • 7.4.1.2.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
    • 7.4.1.3. Rest of North America
      • 7.4.1.3.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
      • 7.4.1.3.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)

8. UK and European Union Hepatitis B Vaccine Market, 2020-2030, USD (Million)

• 8.1. Market Overview
• 8.2. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
• 8.3. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
• 8.4.Hepatitis B Vaccine Market: By Region, 2020-2030, USD (Million)
  • 8.4.1.UK and European Union
    • 8.4.1.1. UK
      • 8.4.1.1.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
      • 8.4.1.1.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
    • 8.4.1.2. Germany
      • 8.4.1.2.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
      • 8.4.1.2.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
    • 8.4.1.3. Spain
      • 8.4.1.3.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
      • 8.4.1.3.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
    • 8.4.1.4. Italy
      • 8.4.1.4.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
      • 8.4.1.4.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
    • 8.4.1.5. France
      • 8.4.1.5.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
      • 8.4.1.5.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
    • 8.4.1.6. Rest of Europe
      • 8.4.1.6.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
      • 8.4.1.6.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)

9. Asia Pacific Hepatitis B Vaccine Market, 2020-2030, USD (Million)

• 9.1. Market Overview
• 9.2. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
• 9.3. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
• 9.4.Hepatitis B Vaccine Market: By Region, 2020-2030, USD (Million)
  • 9.4.1.Asia Pacific
    • 9.4.1.1. China
      • 9.4.1.1.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
      • 9.4.1.1.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
    • 9.4.1.2. Japan
      • 9.4.1.2.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
      • 9.4.1.2.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
    • 9.4.1.3. India
      • 9.4.1.3.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
      • 9.4.1.3.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
    • 9.4.1.4. Australia
      • 9.4.1.4.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
      • 9.4.1.4.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
    • 9.4.1.5. South Korea
      • 9.4.1.5.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
      • 9.4.1.5.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
    • 9.4.1.6. Rest of Asia Pacific
      • 9.4.1.6.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
      • 9.4.1.6.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)

10. Latin America Hepatitis B Vaccine Market, 2020-2030, USD (Million)

• 10.1. Market Overview
• 10.2. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
• 10.3. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
• 10.4.Hepatitis B Vaccine Market: By Region, 2020-2030, USD (Million)
  • 10.4.1.Latin America
    • 10.4.1.1. Brazil
      • 10.4.1.1.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
      • 10.4.1.1.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
    • 10.4.1.2. Mexico
      • 10.4.1.2.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
      • 10.4.1.2.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
    • 10.4.1.3. Rest of Latin America
      • 10.4.1.3.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
      • 10.4.1.3.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)

11. Middle East and Africa Hepatitis B Vaccine Market, 2020-2030, USD (Million)

• 11.1. Market Overview
• 11.2. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
• 11.3. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
• 11.4.Hepatitis B Vaccine Market: By Region, 2020-2030, USD (Million)
  • 11.4.1.Middle East and Africa
    • 11.4.1.1. GCC
      • 11.4.1.1.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
      • 11.4.1.1.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
    • 11.4.1.2. Africa
      • 11.4.1.2.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
      • 11.4.1.2.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
    • 11.4.1.3. Rest of Middle East and Africa
      • 11.4.1.3.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
      • 11.4.1.3.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)

12. Company Profile

• 12.1. Beijing Minhai Biotechnology
  • 12.1.1. Company Overview
  • 12.1.2. Financial Performance
  • 12.1.3. Product Portfolio
  • 12.1.4. Strategic Initiatives
• 12.2. CSL Limited
  • 12.2.1. Company Overview
  • 12.2.2. Financial Performance
  • 12.2.3. Product Portfolio
  • 12.2.4. Strategic Initiatives
• 12.3. Dynavax Technologies
  • 12.3.1. Company Overview
  • 12.3.2. Financial Performance
  • 12.3.3. Product Portfolio
  • 12.3.4. Strategic Initiatives
• 12.4. Emergent Biosolutions
  • 12.4.1. Company Overview
  • 12.4.2. Financial Performance
  • 12.4.3. Product Portfolio
  • 12.4.4. Strategic Initiatives
• 12.5. GlaxoSmithKline Biologicals
  • 12.5.1. Company Overview
  • 12.5.2. Financial Performance
  • 12.5.3. Product Portfolio
  • 12.5.4. Strategic Initiatives
• 12.6. Merck & Co, Inc.
  • 12.6.1. Company Overview
  • 12.6.2. Financial Performance
  • 12.6.3. Product Portfolio
  • 12.6.4. Strategic Initiatives
• 12.7. Novartis AG
  • 12.7.1. Company Overview
  • 12.7.2. Financial Performance
  • 12.7.3. Product Portfolio
  • 12.7.4. Strategic Initiatives
• 12.8. Pfizer Inc.
  • 12.8.1. Company Overview
  • 12.8.2. Financial Performance
  • 12.8.3. Product Portfolio
  • 12.8.4. Strategic Initiatives
• 12.9. Sanofi Pasteur
  • 12.9.1. Company Overview
  • 12.9.2. Financial Performance
  • 12.9.3. Product Portfolio
  • 12.9.4. Strategic Initiatives
• 12.10. Serum Institute of India
  • 12.10.1. Company Overview
  • 12.10.2. Financial Performance
  • 12.10.3. Product Portfolio
  • 12.10.4. Strategic Initiatives
• 12.11. Sinovac Biotech
  • 12.11.1. Company Overview
  • 12.11.2. Financial Performance
  • 12.11.3. Product Portfolio
  • 12.11.4. Strategic Initiatives